【摘要】 目的：观察舒眠胶囊联合奥氮平治疗抑郁症伴失眠的疗效。方法：选取70例抑郁症伴失眠患者，按治疗方式不同分为对照组及观察组各35例。对照组应用奥氮平治疗，观察组应用舒眠胶囊联合奥氮平治疗。比较2组临床疗效及不良反应发生情况，比较2组治疗前后中医证候积分、汉密尔顿抑郁量表（HAMD）、世界卫生组织生存质量测定问卷（WHO-QOL-BREF）评分、睡眠质量的变化。结果：治疗8周后，观察组临床疗效总有效率为97.14%，对照组为71.43%,2组比较，差异有统计学意义（P<0.05）。治疗后，2组中医证候积分均较治疗前下降（P<0.05），观察组中医证候积分低于对照组（P<0.05）。治疗8周后，2组HAMD评分均较治疗前下降（P<0.05）,WHO-QOL-BREF评分均较治疗前升高（P<0.05），观察组HAMD评分低于对照组（P<0.05）,WHO-QOL-BREF评分高于对照组（P<0.05）。治疗后，2组睡眠潜伏期均较治疗前缩短（P<0.05），总睡眠时间均较治疗前增加（P<0.05）；观察组睡眠潜伏期短于对照组（P<0.05），总睡眠时间长于对照组（P<0.05）。观察组不良反应发生率为5.71%，对照组为28.57%,2组比较，差异有统计学意义（P<0.05）。结论：舒眠胶囊联合奥氮平治疗抑郁症伴失眠患者能提高临床疗效，缓解患者精神抑郁、情志不舒、多梦易醒、失眠健忘等症状，改善抑郁程度，促进睡眠质量提升，安全性高。更多还原

【Abstract】 Objective:To observe the curative effect of the therapy of Shumian Capsules combined with Olanzapine on depression complicated with insomnia. Methods: A total of 70 patients with depression complicated with insomnia were selected and divided into the control group and the observation group according to different treatment methods,with 35 cases in each group. The control group was treated with Olanzapine,and the observation group was treated with Shumian Capsules combined with Olanzapine. The clinical effects and incidence of adverse reactions,and the changes of traditional Chinese medicine(TCM)syndrome scores,scores of Hamilton Depression Scale(HAMD) and World Health Organization Quality of Life: Brief Version(WHO-QOL-BREF) and sleep quality were compared before and after treatment between the two groups. Results: After eight weeks of treatment, the total clinical effective rate was 97.14% in the observation group and 71.43% in the control group, the difference being significant(P<0.05). After treatment,the TCM syndrome scores in the two groups were decreased when compared with those before treatment(P<0.05),and the TCM syndrome score in the observation group was lower than that in the control group(P<0.05). After treatment,the HAMD scores in the two groups were decreased when compared with those before treatment(P<0.05),and the WHO-QOL-BREF scores were increased when compared with those before treatment(P<0.05); the HAMD score in the observation group was lower than that in the control group,and the WHO-QOL-BREF score was higher than that in the control group(P<0.05). The sleep latency in the observation group was shorter than that in the control group(P<0.05),and the total sleep time was longer than that in the control group(P<0.05). The incidence of adverse reactions was 5.71% in the observation group and 28.57% in the control group, the difference being significant(P<0.05). Conclusion:The therapy of Shumian Capsules combined with Olanzapine can improve the clinical effect on patients with depression complicated with insomnia, mitigate such symptoms as depressed in mind,emotional upsets,dreaminess and multiple arousals,and insomnia and forgetfulness of patients, reduce the depression degree, and promote the improvement of sleep quality with great safety.更多还原